Astrocytes - Friends or foes in multiple sclerosis?

GLIA

Volumn 55, Issue 13, 2007, Pages 1300-1312

  Williams, Anna ^a,b   Piaton, Gabrièle ^a   Lubetzki, Catherine ^a  

^a INSERM   (France)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Demyelination; Myelin; Remyelination

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MATRIX METALLOPROTEINASE; NESTIN; SOMATOMEDIN C; VIMENTIN;

ANTIGEN PRESENTATION; ASTROCYTE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; CELL ACTIVITY; CELL DAMAGE; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DEMYELINATION; GLIA CELL; HYPERTROPHY; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE FIBER DEGENERATION; NERVE FIBER GROWTH; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMYELINIZATION; REVIEW;

ASTROCYTES; AXONS; CICATRIX; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE DEGENERATION; OLIGODENDROGLIA;

EID: 34548206670     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20546     Document Type: Review

References (209)

1. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G, Probert L. 1998. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: Models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 153:801-813.
2. Albrecht PJ, Murtie JC, Ness JK, Redwine JM, Enterline JR, Armstrong RC, Levison SW. 2003. Astrocytes produce CNTF during the remyelination phase of viral-induced spinal cord demyelination to stimulate FGF-2 production. Neurobiol Dis 13:89-101.
3. Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, Yong VW, Nuttall RK, Pennington CJ, Edwards DR, Bar-Or A. 2003. Determinants of human B cell migration across brain endothelial cells. J Immunol 170:4497-4505.
4. Anton G, Wohlwill F. 1912. Multiple nicht eitrige Encephalomyelitis und Multiple Skleroze. Z ges Neurol Psych 12:31-99.
5. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. 2001. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4:1116-1122.
6. Asakura K, Rodriguez M. 1998. A unique population of circulating autoantibodies promotes central nervous system remyelination. Mult Scler 4:217-221.
7. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M. 2003. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136:46-53.
8. Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, Luo NL, Banine F, Liu Y, Chang A, Trapp BD, Bebo BF, Rao MS, Sherman LS. 2005. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 11:966-972.
9. Bajetto A, Barbero S, Bonavia R, Piccioli P, Pirani P, Florio T, Schettini G. 2001. Stromal cell-derived factor-1α induces astrocyte proliferation through the activation of extracellular signal-regulated kinases 1/2 pathway. J Neurochem 77:1226-1236.
10. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. 1994. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 24:2040-2048.
11. Bannerman P, Hahn A, Soulika A, Gallo V, Pleasure D. 2007. Astrogliosis in EAE spinal cord: Derivation from radial glia, and relationships to oligodendroglia. Glia 55:57-64.
12. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. 1999. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163:5133-5144.
13. Barcellos LF, Thomson G, Carrington M, Schafer J, Begovich AB, Lin P, Xu XH, Min BQ, Marti D, Klitz W. 1997. Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis. Evidence of a new susceptibility locus in Caucasian and Chinese patients. JAMA 278:1256-1261.
14. Barna BP, Pettay J, Barnett GH, Zhou P, Iwasaki K, Estes ML. 1994. Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor (TNF) or antibody to the 55-kDa TNF receptor. J Neuroimmunol 50:101-107.
15. Baron W, Colognato H, Ffrench-Constant C. 2005. Integrin-growth factor interactions as regulators of oligodendroglial development and function. Glia 49:467-479.
16. Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti F. 1995. Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 14:717-730.
17. Berman JW, Guida MP, Warren J, Amat J, Brosnan CF. 1996. Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat. J Immunol 156:3017-3023.
18. Bitsch A, Kuhlmann T, Da Costa C, Bunkowski S, Polak T, Bruck W. 2000. Tumour necrosis factor α mRNA expression in early multiple sclerosis lesions: Correlation with demyelinating activity and oligodendrocyte pathology. Glia 29:366-375.
19. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. 2001. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57:1248-1252.
20. Blakemore WF, Gilson JM, Crang AJ. 2003. The presence of astrocytes in areas of demyelination influences remyelination following transplantation of oligodendrocyte progenitors. Exp Neurol 184:955-963.
21. Bo L, Mork S, Kong PA, Nyland H, Pardo CA, Trapp BD. 1994. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 51:135-146.
22. Border WA, Ruoslahti E. 1992. Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 90:1-7.
23. Boyle EA, McGeer PL. 1990. Cellular immune response in multiple sclerosis plaques. Am J Pathol 137:575-584.
24. Bridges RJ, Esslinger CS. 2005. The excitatory amino acid transporters: Pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol Ther 107:271-285.
25. Bugga L, Gadient RA, Kwan K, Stewart CL, Patterson PH. 1998. Analysis of neuronal and glial phenotypes in brains of mice deficient in leukemia inhibitory factor. J Neurobiol 36:509-524.
26. Butter C, O'Neill JK, Baker D, Gschmeissner SE, Turk JL. 1991. An immunoelectron microscopical study of the expression of class II major histocompatibility complex during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice. J Neuroimmunol 33:37-42.
27. Calderon TM, Eugenin EA, Lopez L, Kumar SS, Hesselgesser J, Raine CS, Berman JW. 2006. A role for CXCL12 (SDF-1α) in the pathogenesis of multiple sclerosis: Regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 177:27-39.
28. Cammer W. 2000. Effects of TNFα on immature and mature oligodendrocytes and their progenitors in vitro. Brain Res 864:213-219.
29. Cannella B, Pitt D, Capello E, Raine CS. 2000. Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. Am J Pathol 157:933-943.
30. Charcot JM. 1868. Histologic de la sclerose en plaques. Gaz Hop de Paris 41:554-556, 558.
31. Cook DN, Chen SC, Sullivan LM, Manfra DJ, Wiekowski MT, Prosser DM, Vassileva G, Lira SA. 2001. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol 21:3159-3165.
32. Corley SM, Ladiwala U, Besson A, Yong VW. 2001. Astrocytes attenuate oligodendrocyte death in vitro through an α (6) integrin-laminindependent mechanism. Glia 36:281-294.
33. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, Van der Valk P, De Groot CJ. 1997. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol (Berlin) 94:590-598.
34. Crocker SJ, Whitmire JK, Frausto RF, Chertboonmuang P, Soloway PD, Whitton JL, Campbell IL. 2006. Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am J Pathol 169:2104-2116.
35. D'Amelio FE, Smith ME, Eng LF. 1990. Sequence of tissue responses in the early stages of experimental allergic encephalomyelitis (EAE): Immunohistochemical, light microscopic, and ultrastructural observations in the spinal cord. Glia 3:229-240.
36. da Cunha A, Jefferson JA, Jackson RW, Vitkovic L. 1993. Glial cell-specific mechanisms of TGF-β 1 induction by IL-1 in cerebral cortex. J Neuroimmunol 42:71-85.
37. De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, Van der Valk P. 1997. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 56:10-20.
38. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL. 1998. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121(Part 8):1469-1477.
39. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL. 2001. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65-70.
40. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. 2006. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129(Part 6):1507-1516.
41. Demerens C, Stankoff B, Logak M, Anglade P, Allinquant B, Couraud F, Zalc B, Lubetzki C. 1996. Induction of myelination in the central nervous system by electrical activity. Proc Natl Acad Sci USA 93:9887-9892.
42. Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM. 2006. Protein coexpression with axonal injury in multiple sclerosis plaques. Acta Neuropathol (Berlin) 111:289-299.
43. Diemel LT, Jackson SJ, Cuzner ML. 2003. Role for TGF-β1, FGF-2 and PDGF-AA in a myelination of CNS aggregate cultures enriched with macrophages J Neurosci Res 74:858-867.
44. Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, van den Oord J, Sciot R, Meinhardt T, Hammerling G, Opdenakker G, Arnold B. 1999. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104:1507-1515.
45. Dziembowska M, Tham TN, Lau P, Vitry S, Lazarini F, Dubois-Dalcq M. 2005. A role for CXCR4 signaling in survival and migration of neural and oligodendrocyte precursors. Glia 50:258-269.
46. Eddleston M, Mucke L. 1993. Molecular profile of reactive astrocytesimplications for their role in neurologic disease. Neuroscience 54:15-36.
47. Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. 1998. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 28:2178-2187.
48. Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, Casetta I, Paolino E, Granieri E, Dallocchio F. 2006. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 12:294-301.
49. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. 2004. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24:2143-2155.
50. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. 2002. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3:944-950.
51. Fischer FR, Santambrogio L, Luo Y, Berman MA, Hancock WW, Dorf ME. 2000. Modulation of experimental autoimmune encephalomyelitis: Effect of altered peptide ligand on chemokine and chemokine receptor expression. J Neuroimmunol 110:195-208.
52. Fontana A, Fierz W, Wekerle H. 1984. Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature 307:273-276.
53. Franciotta D, Bergamaschi R, Martino G, Zardini E, Desina G, Cosi V. 1999. Tumor necrosis factor-a and its soluble receptors in plasma and cerebrospinal fluid of multiple sclerosis patients treated with methylprednisolone. Eur Cytokine Netw 10:431-436.
54. Frank JA, Richert N, Lewis B, Bash C, Howard T, Civil R, Stone R, Eaton J, McFarland H, Leist T. 2002. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. Mult Scler 8:24-29.
55. Franklin RJ, Crang AJ, Blakemore WF. 1991. Transplanted type-1 astrocytes facilitate repair of demyelinating lesions by host oligodendrocytes in adult rat spinal cord. J Neurocytol 20:420-430.
56. Frei K, Fredrikson S, Fontana A, Link H. 1991. Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 31:147-153.
57. Furie MB, Randolph GJ. 1995. Chemokines and tissue injury. Am J Pathol 146:1287-1301.
58. Genain CP, Cannella B, Hauser SL, Raine CS. 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5:170-175.
59. Genoud S, Maricic I, Kumar V, Gage FH. 2005. Targeted expression of IGF-1 in the central nervous system fails to protect mice from experimental autoimmune encephalomyelitis. J Neuroimmunol 168:40-45.
60. Gijbels K, Galardy RE, Steinman L. 1994. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94:2177-2182.
61. Gimenez MA, Sim JE, Russell JH. 2004. TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation. J Neuroimmunol 151:116-125.
62. Glabinski AR, Tani M, Strieter RM, Tuohy VK, Ransohoff RM. 1997. Synchronous synthesis of α- and 3-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 150:617-630.
63. Godiska R, Chantry D, Dietsch GN, Gray PW. 1995. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 58:167-176.
64. Gomez-Pinilla F, Vu L, Cotman CW. 1995. Regulation of astrocyte proliferation by FGF-2 and heparan sulfate in vivo. J Neurosci 15(3 Part 1):2021-2029.
65. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, Noelle RJ, Becher B. 2005. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11:328-334.
66. Han Y, He T, Huang DR, Pardo CA, Ransohoff RM. 2001. TNF-α mediates SDF-1 α-induced NF-κ B activation and cytotoxic effects in primary astrocytes. J Clin Invest 108:425-435.
67. Hargreaves DC, Hyman PL, Lu TT, Ngo VN, Bidgol A, Suzuki G, Zou YR, Littman DR, Cyster JG. 2001. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 194:45-56.
68. Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, Faia K, Fituri O, Rottman JB, Charo IF. 2001. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 108:679-688.
69. Hayashi M, Luo Y, Laning J, Strieter RM, Dorf ME. 1995. Production and function of monocyte chemoattractant protein-1 and other β-chemokines in murine glial cells. J Neuroimmunol 60:143-150.
70. Hinks GL, Franklin RJ. 1999. Distinctive patterns of PDGF-A, FGF-2, IGF-I, and TGF-β1 gene expression during remyelination of experimentally-induced spinal cord demyelination Mol Cell Neurosci 14:153-168.
71. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. 2003. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 991:214-228.
72. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. 1999. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530-534.
73. Horwitz MS, Evans CF, Klier FG, Oldstone MB. 1999. Detailed in vivo analysis of interferon-γ induced major histocompatibility complex expression in the the central nervous system: Astrocytes fail to express major histocompatibility complex class I, II, molecules. Lab Invest 79:235-242.
74. Hsieh J, Aimone JB, Kaspar BK, Kuwabara T, Nakashima K, Gage FH. 2004. IGF-I instructs multipotent adult neural progenitor cells to become oligodendrocytes. J Cell Biol 164:111-122.
75. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM. 2001. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 193:713-726.
76. Hulkower K, Brosnan CF, Aquino DA, Cammer W, Kulshrestha S, Guida MP, Rapoport DA, Berman JW. 1993. Expression of CSF-1, cfms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. J Immunol 150:2525-2533.
77. Hulshof S, van Haastert ES, Kuipers HF, van den Elsen PJ, De Groot CJ, van der Valk P, Ravid R, Biber K. 2003. CX3CL1 and CX3CR1 expression in human brain tissue: Noninflammatory control versus multiple sclerosis. J Neuropathol Exp Neurol 62:899-907.
78. Hurwitz AA, Lyman WD, Berman JW. 1995. Tumor necrosis factor a and transforming growth factor β upregulate astrocyte expression of monocyte chemoattractant protein-1. J Neuroimmunol 57:193-198.
79. Ip NY, Wiegand SJ, Morse J, Rudge JS. 1993. Injury-induced regulation of ciliary neurotrophic factor mRNA in the adult rat brain. Eur J Neurosci 5:25-33.
80. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, Fields RD. 2006. Astrocytes promote myelination in response to electrical impulses. Neuron 49:823-832.
81. Jakob A. 1915. Zur Pathologie der diffusen infiltrativen Encephalomyelitis in ihren Beziehungen zur diffusen und multiplen. Skleroze Z ges Neurol Psych 27:290-320.
82. Jenkins HG, Ikeda H. 1992. Tumour necrosis factor causes an increase in axonal transport of protein and demyelination in the mouse optic nerve. J Neurol Sci 108:99-104.
83. John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, Raine CS, Brosnan CF. 2002. Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 8:1115-1121.
84. Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, Rees RC. 1997. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 158:2327-2333.
85. Jurynczyk M, Jurewicz A, Bielecki B, Raine CS, Selmaj K. 2005. Inhibition of notch signaling enhances tissue repair in an animal model of multiple sclerosis. J Neuroimmunol 170:3-10.
86. Kanesaka T, Mori M, Hattori T, Oki T, Kuwabara S. 2006. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 77:185-188.
87. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. 2003. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 53:174-180.
88. Karpus WJ, Kennedy KJ. 1997. MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 62:681-687.
89. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. 2003. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301:839-842.
90. Komoly S, Hudson LD, Webster HD, Bondy CA. 1992. Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci USA 89:1894-1898.
91. Kort JJ, Kawamura K, Fugger L, Weissert R, Forsthuber TG. 2006. Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice. J Neuroimmunol 173:23-34.
92. Krogsgaard M, Wucherpfennig KW, Cannella B, Hansen BE, Svejgaard A, Pyrdol J, Ditzel H, Raine C, Engberg J, Fugger L. 2000. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J Exp Med 191:1395-1412.
93. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, Hofbauer M, Farina C, Derfuss T, Hartle C, Newcombe J, Hohlfeld R, Meinl E. 2006. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129(Part 1):200-211.
94. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, Railed SL, Hess DM, Serafini B, Aloisi F, Wekerle H, Hohlfeld R, Meinl E. 2005. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201:195-200.
95. Kuroda Y, Shimamoto Y. 1991. Human tumor necrosis factor-α augments experimental allergic encephalomyelitis in rats. J Neuroimmunol 34:159-164.
96. Lachapelle F, Bachelin C, Moissonnier P, Nait-Oumesmar B, Hidalgo A, Fontaine D, Baron-Van Evercooren A. 2005. Failure of remyelination in the nonhuman primate optic nerve. Brain Pathol 15:198-207.
97. Larsen PH, DaSilva AG, Conant K, Yong VW. 2006. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J Neurosci 26:2207-2214.
98. Larsen PH, Wells JE, Stallcup WB, Opdenakker G, Yong VW. 2003. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 23:11127-11135.
99. Larsen PH, Yong VW. 2004. The expression of matrix metalloproteinase-12 by oligodendrocytes regulates their maturation and morphological differentiation. J Neurosci 24:7597-7603.
100. Lee MA, Blamire AM, Pendlebury S, Ho KH, Mills KR, Styles P, Palace J, Matthews PM. 2000. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 57:65-70.
101. Lee SC, Moore GR, Golenwsky G, Raine CS. 1990. Multiple sclerosis: A role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study. J Neuropathol Exp Neurol 49:122-136.
102. Levine JB, Kong J, Nadler M, Xu Z. 1999. Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS). Glia 28:215-224.
103. Li W, Quigley L, Yao DL, Hudson LD, Brenner M, Zhang BJ, Brocke S, McFarland HF, Webster HD. 1998. Chronic relapsing experimental autoimmune encephalomyelitis: Effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects. J Neuropathol Exp Neurol 57:426-438.
104. Lindberg RL, De Groot CJ, Montagne L, Freitag P, van der Valk P, Kappos L, Leppert D. 2001. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124(Part 9):1743-1753.
105. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R. 2002. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8:620-624.
106. Liu X, Yao DL, Bondy CA, Brenner M, Hudson LD, Zhou J, Webster HD. 1994. Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis Mol Cell Neurosci 5:418-430.
107. Liu ZG, Haelens A, Wuyts A, Struyf S, Pang XW, Proost P, Chen WF, van Damme J. 1996. Isolation of a lymphocyte chemotactic factor produced by the murine thymic epithelial cell line MTEC1: Identification as a 30 kDa glycosylated form of MCP-1. Eur Cytokine Netw 7:381-388.
108. Louis JC, Magal E, Takayama S, Varon S. 1993. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science 259:689-692.
109. Lovett-Racke AE, Bittner P, Cross AH, Carlino JA, Racke MK. 1998. Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J Clin Invest 101:1797-1804.
110. Lubetzki C, Williams A, Stankoff B. 2005. Promoting repair in multiple sclerosis: Problems and prospects. Curr Opin Neurol 18:237-244.
111. Luo Y, Laning J, Hayashi M, Hancock PR, Rollins B, Dorf ME. 1994. Serologic analysis of the mouse β chemokine JE/monocyte chemoattractant protein-1. J Immunol 153:3708-3716.
112. Mackay F, Tangye SG. 2004. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 4:347-354.
113. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697-1710.
114. Maeda A, Sobel RA. 1996. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55:300-309.
115. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. 2004. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 148:11-23.
116. Maimone D, Gregory S, Arnason BG, Reder AT. 1991. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32:67-74.
117. Malhotra SK, Shnitka TK. 1994. Adaptive plasticity and diversity among reactive astrocytes in central nervous system lesions. Biomed Lett 196:273-302.
118. Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, Rosenberg GA. 2001. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devie's neuromyelitis optica. Brain 124(Part 3):493-498.
119. Mansour H, Asher R, Dahl D, Labkovsky B, Perides G, Bignami A. 1990. Permissive and non-permissive reactive astrocytes: Immunofluorescence study with antibodies to the glial hyaluronate-binding protein. J Neurosci Res 25:300-311.
120. Mason JL, Suzuki K, Chaplin DD, Matsushima GK. 2001. Interleukin1β promotes repair of the CNS. J Neurosci 21:7046-7052.
121. Massaro AR, Soranzo C, Carnevale A. 1997. Cerebrospinal-fluid ciliary neurotrophic factor in neurological patients. Eur Neurol 37:243-246.
122. Matsumoto Y, Ohmori K, Fujiwara M. 1992. Immune regulation by brain cells in the central nervous system: Microglia but not astrocytes present myelin basic protein to encephalitogenic T cells under in vivo-mimicking conditions. Immunology 76:209-216.
123. Matute C, Sanchez-Gomez MV, Martinez-Millan L, Miledi R. 1997. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci USA 94:8830-8835.
124. Maysami S, Nguyen D, Zobel F, Pitz C, Heine S, Hopfner M, Stangel M. 2006. Modulation of rat oligodendrocyte precursor cells by the chemokine CXCL12. Neuroreport 17:1187-1190.
125. McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP. 1998. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 4:291-297.
126. McKinnon RD, Piras G, Ida JA Jr, Dubois-Dalcq M. 1993. A role for TGF-β in oligodendrocyte differentiation. J Cell Biol 121:1397-1407.
127. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. 1998. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study. J Neuroimmunol 86:20-29.
128. McMorris FA, Mozell RL, Carson MJ, Shinar Y, Meyer RD, Marchetti N. 1993. Regulation of oligodendrocyte development and central nervous system myelination by insulin-like growth factors. Ann N Y Acad Sci 692:321-334.
129. McMorris FA, Smith TM, DeSalvo S, Furlanetto RW. 1986. Insulin-like growth factor I/somatomedin C: A potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA 83:822-826.
130. Mozell RL, McMorris FA. 1991. Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J Neurosci Res 30:382-390.
131. Müller E. 1904. Pathologische anatomie und pathogenese. In: Fisher G, editor. Die multiple Skleroze des Gehirns und Ruckenmarks: Jena, pp 300-344.
132. Myer DJ, Gurkoff GG, Lee SM, Hovda DA, Sofroniew MV. 2006. Essential protective roles of reactive astrocytes in traumatic brain injury. Brain 129(Part 10):2761-2772.
133. Navikas V, Matusevicius D, Soderstrom M, Fredrikson S, Kivisakk P, Ljungdahl A, Hojeberg B, Link H. 1996. Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J Neuroimmunol 64:63-69.
134. Nikcevich KM, Gordon KB, Tan L, Hurst SD, Kroepfl JF, Gardinier M, Barrett TA, Miller SD. 1997. IFN-γ-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigenspecific T cells. J Immunol 158:614-621.
135. Norenberg MD. 1994. Astrocyte responses to CNS injury. J Neuropathol Exp Neurol 53:213-220.
136. Odemis V, Moepps B, Gierschik P, Engele J. 2002. Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by up-regulating CXCR4 cell surface expression. Implications for brain inflammation. J Biol Chem 277:39801-39808.
137. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH. 2003. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 171:2725-2733.
138. Paasivuo R, Saksela E. 1983. Non-specific binding of mouse immunoglobulins by swollen-bodied astrocytes-a potential source of confusion in human brain immunohistochemistry. Acta Neuropathol (Berlin) 59:103-108.
139. Padberg F, Feneberg W, Schmidt S, Schwarz MJ, Korschenhausen D, Greenberg BD, Nolde T, Muller N, Trapmann H, Konig N, Möller HJ, Hampel H. 1999. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol 99:218-223.
140. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL. 1998. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 152:729-741.
141. Pekny M, Johansson CB, Eliasson C, Stakeberg J, Wallen A, Perlmann T, Lendahl U, Betsholtz C, Berthold CH, Frisen J. 1999. Abnormal reaction to central nervous system injury in mice lacking glial fibrillary acidic protein and vimentin. J Cell Biol 145:503-514.
142. Pekny M, Nilsson M. 2005. Astrocyte activation and reactive gliosis. Glia 50:427-434.
143. Perentes E, Rubinstein LJ. 1986. Non-specific binding of mouse myeloma IgM immunoglobulins by human myelin sheaths and astrocytes. A potential complication of nervous system immunoperoxidase histochemistry. Acta Neuropathol (Berlin) 70:284-288.
144. Pitt D, Nagelmeier IE, Wilson HC, Raine CS. 2003. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 61:1113-1120.
145. Plant SR, Arnett HA, Ting JP. 2005. Astroglial-derived lymphotoxin-α exacerbates inflammation and demyelination, but not remyelination. Glia 49:1-14.
146. Plo I, Ghandour S, Feutz AC, Clanet M, Laurent G, Bettaieb A. 1999. Involvement of de novo ceramide biosynthesis in lymphotoxin-induced oligodendrocyte death. Neuroreport 10:2373-2376.
147. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910.
148. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. 1995. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α. Proc Natl Acad Sci USA 92:11294-11298.
149. Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J. 1998. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 102:1045-1050.
150. Raine CS, Bonetti B, Cannella B. 1998. Multiple sclerosis: Expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque. Rev Neurol (Paris) 154:577-585.
151. Ransohoff RM, Estes ML. 1991. Astrocyte expression of major histocompatibility complex gene products in multiple sclerosis brain tissue obtained by stereotactic biopsy. Arch Neurol 48:1244-1246.
152. Ransohoff RM, Hamilton TA, Tani M, Stoler MH, Shick HE, Major JA, Estes ML, Thomas DM, Tuohy VK. 1993. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 7:592-600.
153. Rash JE, Yasumura T, Dudek FE, Nagy JL 2001. Cell-specific expression of connexins and evidence of restricted gap junctional coupling between glial cells and between neurons. J Neurosci 21:1983-2000.
154. Ricard D, Stankoff B, Bagnard D, Aguera M, Rogemond V, Antoine JC, Spassky N, Zalc B, Lubetzki C, Belin MF, Honnorat J. 2000. Differential expression of collapsin response mediator proteins (CRMP/ULIP) in subsets of
155. Ridet JL, Malhotra SK, Privat A, Gage FH. 1997. Reactive astrocytes: Cellular and molecular cues to biological function. Trends Neurosci 20:570-577.
156. Rindfleisch E. 1863. Histologisches Detail zur grauen Degeneration von Gehirn und Rückenmarck. Arch Pathol Anat Physiol Klin Med 26: 474-483.
157. Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL. 1994. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol 153:3811-3821.
158. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 172:1193-1200.
159. Salter MG, Fern R. 2005. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438:1167-1171.
160. Saneto RP, Low KG, Melner MH, de Vellis J. 1988. Insulin/insulin-like growth factor I, other epigenetic modulators of myelin basic protein expression in isolated oligodendrocyte progenitor cells. J Neurosci Res 21:210-219.
161. Schonrock LM, Gawlowski G, Bruck W 2000. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett 294:45-48.
162. Seifert T, Bauer J, Weissert R, Fazekas F, Storch MK. 2007. Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. Acta Neuropathol (Berlin) 113:195-203.
163. Selmaj K, Papierz W, Glabinski A, Kohno T. 1995. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 56:135-141.
164. Selmaj K, Raine CS, Cannella B, Brosnan CF. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87:949-954.
165. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. 2004. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164-174.
166. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. 1998. Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 84:238-249.
167. Smith KJ, Kapoor R, Felts PA. 1999. Demyelination: The role of reactive oxygen and nitrogen species. Brain Pathol 9:69-92.
168. Smith ME, Sommer MA. 1992. Association between cell-mediated demyelination and astrocyte stimulation. Prog Brain Res 94:411-422.
169. Soos JM, Morrow J, Ashley TA, Szente BE, Bikoff EK, Zamvil SS. 1998. Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J Immunol 161:5959-5966.
170. Spassky N, de Castro F, Le Bras B, Heydon K, Queraud-LeSaux F, Bloch-Gallego E, Chedotal A, Zalc B, Thomas JL. 2002. Directional guidance of oligodendroglial migration by class 3 semaphorins and netrin-1. J Neurosci 22:5992-6004.
171. Stankoff B, Aigrot MS, Noel F, Wattilliaux A, Zalc B, Lubetzki C. 2002. Ciliary neurotrophic factor (CNTF) enhances myelin formation: A novel role for CNTF and CNTF-related molecules. J Neurosci 22: 9221-9227.
172. Steinman L. 1996. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 85:299-302.
173. Stevens B, Porta S, Haak LL, Gallo V, Fields RD. 2002. Adenosine: A neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 36:855-868.
174. Stidworthy MF, Genoud S, Li WW, Leone DP, Mantei N, Suter U, Franklin RJ. 2004. Notch1l and Jaggedl are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination. Brain 127(Part 9):1928-1941.
175. Sugimoto Y, Taniguchi M, Yagi T, Akagi Y, Nojyo Y, Tamamaki N. 2001. Guidance of glial precursor cell migration by secreted cues in the developing optic nerve. Development 128:3321-3330.
176. Sunnemark D, Eltayeb S, Nilsson M, Wallstrom E, Lassmann H, Olsson T, Berg AL, Ericsson-Dahlstrand A. 2005. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoproteininduced experimental autoimmune encephalomyelitis: Kinetics and cellular origin. J Neuroinflammation 2:17
177. Talbott JF, Loy DN, Liu Y, Qiu MS, Bunge MB, Rao MS, Whittemore SR. 2005. Endogenous Nkx2.2+/01ig2+ oligodendrocyte precursor cells fail to remyelinate the demyelinated adult rat spinal cord in the absence of astrocytes. Exp Neurol 192:11-24.
178. Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD. 1998. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-γ-activated SJL/J astrocytes. J Immunol 160:4271-4279.
179. Tanuma N, Sakuma H, Sasaki A, Matsumoto Y. 2006. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol (Berlin) 112:195-204.
180. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr, Goeddel DV. 1991. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 88:9292-9296.
181. Taub DD, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. 1996. Chemokines and T lymphocyte activation. I. β chemokines costimulate human T lymphocyte activation in vitro. J Immunol 156: 2095-2103.
182. Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T. 1997. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-α in the central nervous system. Eur J Immunol 27:905-913.
183. Taylor PC, Williams RO, Feldmann M. 2004. Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol 15:557-563.
184. Tchelingerian JL, Monge M, Le Saux F, Zalc B, Jacque C. 1995. Differential oligodendroglial expression of the tumor necrosis factor receptors in vivo and in vitro. J Neurochem 65:2377-2380.
185. Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmstrom P. 2004. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 152:183-190.
186. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 53:457-465.
187. Tsai HH, Frost E, To V, Robinson S, Ffrench-Constant C, Geertman R, Ransohoff RM, Miller RH. 2002. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 110:373-383.
188. Tuohy TM, Wallingford N, Liu Y, Chan FH, Rizvi T, Xing R, Bebo B, Rao MS, Sherman LS. 2004. CD44 overexpression by oligodendrocytes: A novel mouse model of inflammation-independent demyelination and dysmyelination. Glia 47:335-345.
189. Uhm JH, Dooley NP, Oh LY, Yong VW. 1998. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix Glia 22:53-63.
190. Ulrich R, Baumgartner W, Gerhauser I, Seeliger F, Haist V, Deschl U, Alldinger S. 2006. MMP-12, MMP-3, and TIMP-1 are markedly upregulated in chronic demyelinating theiler murine encephalomyelitis. J Neuropathol Exp Neurol 65:783-793.
191. Vallejo-Illarramendi A, Domercq M, Perez-Cerda F, Ravid R, Matute C. 2006. Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis 21:154-164.
192. Van Der Voorn P, Tekstra J, Beelen RH, Tensen CP, Van Der Valk P, De Groot CJ. 1999. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 154:45-51.
193. van Horssen J, Vos CM, Admiraal L, van Haastert ES, Montagne L, van der Valk P, de Vries HE. 2006. Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol Appl Neurobiol 32:585-593.
194. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. 1996. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531-1534.
195. Venance L, Cordier J, Monge M, Zalc B, Glowinski J, Giaume C. 1995. Homotypic and heterotypic coupling mediated by gap junctions during glial cell differentiation in vitro. Eur J Neurosci 7:451-461.
196. Wang D, Ayers MM, Catmull DV, Hazelwood LJ, Bernard CC, Orian JM. 2005. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia 51:235-240.
197. Wang S, Sdrulla AD, diSibio G, Bush G, Nofziger D, Hicks C, Weinmaster G, Barres BA. 1998. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 21:63-75.
198. Wang X, Tay SS, Ng YK. 2000. An immunohistochemical study of neuronal and glial cell reactions in retinae of rats with experimental glaucoma. Exp Brain Res 132:476-484.
199. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K. 1999. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53:1397-1401.
200. Wilhelmsson U, Li L, Pekna M, Berthold CH, Blom S, Eliasson C, Renner O, Bushong E, Ellisman M, Morgan TE, Pekny M. 2004. Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neurosci 24:5016-5021.
201. Willenborg DO, Fordham SA, Cowden WB, Ramshaw IA. 1995. Cytokines and murine autoimmune encephalomyelitis: Inhibition or enhancement of disease with antibodies to select cytokines, or by delivery of exogenous cytokines using a recombinant vaccinia virus system. Scand J Immunol 41:31-41.
202. Woodroofe MN, Cuzner ML. 1993. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: Detection by non-radioactive in situ hybridization. Cytokine 5:583-588.
203. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. 2007. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27:697-709.
204. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against α 4 β 1 integrin. Nature 356:63-66.
205. Yong VW. 1999. The potential use of MMP inhibitors to treat CNS diseases. Expert Opin Investig Drugs 8:255-268.
206. Yong VW, Power C, Forsyth P, Edwards DR. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502-511.
207. Youssef S, Wildbaum G, Karin N. 1999. Prevention of experimental autoimmune encephalomyelitis by MIP-1α and MCP-1 naked DNA vaccines. J Autoimmun 13:21-29.
208. Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, Holden J, Clark-Lewis I, Overall CM, Power C. 2003. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 6:1064-1071.
209. Zhang Y, Taveggia C, Melendez-Vasquez C, Einheber S, Raine CS, Salzer JL, Brosnan CF, John GR. 2006. Interleukin-11 potentiates oligodendrocyte survival and maturation, and myelin formation. J Neurosci 26:12174-12185.